HYDERABAD, India -- (Business Wire)
Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has
launched Eszopiclone Tablets (C-IV) 1 mg, 2 mg and 3 mg, a therapeutic
equivalent generic version of LUNESTA® (eszopiclone) tablets C-IV in the
US market on April 15, 2014, following the approval by the United States
Food & Drug Administration (USFDA).
The LUNESTA® (eszopiclone) tablets C-IV brand and generic combined had
U.S. sales of approximately $887 Million MAT for the most recent twelve
months ending in January 2014 according to IMS Health*.
Dr. Reddy’s Eszopiclone Tablets (C-IV) 1 mg is available in bottle
counts of 30. Eszopiclone Tablets (C-IV) 2 mg and 3 mg are available in
bottle counts of 100.
Disclaimer
This press release includes forward-looking statements, as defined in
the U.S. Private Securities Litigation Reform Act of 1995. We have based
these forward-looking statements on our current expectations and
projections about future events. Such statements involve known and
unknown risks, uncertainties and other factors that may cause actual
results to differ materially. Such factors include, but are not limited
to, changes in local and global economic conditions, our ability to
successfully implement our strategy, the market acceptance of and demand
for our products, our growth and expansion, technological change and our
exposure to market risks. By their nature, these expectations and
projections are only estimates and could be materially different from
actual results in the future.
About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global
pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses -
Pharmaceutical Services and Active Ingredients, Global Generics and
Proprietary Products – Dr. Reddy’s offers a portfolio of products and
services including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Major therapeutic focus is
on gastro-intestinal, cardiovascular, diabetology, oncology, pain
management and anti-infective. Major markets include India, USA,
Russia-CIS and Europe apart from other select geographies within
Emerging Markets.For more information, log on to: www.drreddys.com
LUNESTA® is a registered trademark of Sunovion
Pharmaceuticals Inc.
*IMS National Sales Perspectives: Retail and
Non-Retail MAT January 2014
Contacts:
Dr. Reddy’s Laboratories Ltd.
Investors and
Financial Analysts:
Kedar Upadhye, +91-40-66834297
kedaru@drreddys.com
or
Saunak
Savla, +91-40-49002135
saunaks@drreddys.com
or
Milan
Kalawadia (USA), +1 609-375-9831
mkalawadia@drreddys.com
or
Media:
SVS
Chowdary, +91-40-49002448
chowdaryl@drreddys.com
Source: Dr. Reddy’s Laboratories Ltd.
© 2024 Canjex Publishing Ltd. All rights reserved.